Showing results (641-650 of 2,891) with videos related to
Sort By:
Pageof 290
JAMA Internal Medicine|February 28, 2017
Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial FibrillationPeter Brønnum Nielsen, Torben Bjerregaard Larsen, Flemming Skjøth, et al.Family Practice|July 17, 2007
'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitationMiren Jones, Kate Jolly, James Raftery, et al.The American Journal of Cardiology|August 25, 2004
Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillationDwayne S G Conway, Peter Buggins, Elizabeth Hughes, et al.Thrombosis and Haemostasis|May 27, 2011
Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patientsIsla M Ogilvie, Sharon A Welner, Warren Cowell, et al.BMJ Clinical Evidence|November 15, 2011
Atrial fibrillation (chronic)Deirdre A Lane, Stavros Apostolakis, Christopher J Boos, et al.Chest|December 16, 2014
Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial FibrillationYutao Guo, Hao Wang, Yingchun Tian, et al.Chest|November 21, 2014
The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation projectGregory Y H Lip, Nicolas Clementy, Bertrand Pierre, et al.BMC Medicine|October 12, 2022
Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysisWengen Zhu, Zexuan Wu, Yugang Dong, et al.Current Heart Failure Reports|February 17, 2022
Telemedical Monitoring Based on Implantable Devices-the Evolution Beyond the CardioMEMS™ TechnologyAgnieszka Kotalczyk, Jacopo F Imberti, Gregory Y H Lip, et al.Journal of the American College of Cardiology|March 16, 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc scoreGregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, et al.Pageof 290